|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||486.43 g/mol g·mol−1|
|3D model (JSmol)|
Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).
Vilanterol is available in following combinations:
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|